Bailard’s Biocept, Inc. BIOC Stock Holding History

Bailard’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,403	Closed	-$152K	–	825
2021 Q4	$152K	Buy	+1,403	New	+$162K	﹤0.01%	703

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bailard's BIOC Position: Q1 2022 in Review

Bailard sold out of Biocept, Inc. (BIOC) in Q1 2022, closing a stake of 1,403 shares — an estimated $152K sold.

Bailard first reported a position in BIOC in Q4 2021 and held it in 1 quarter. The position peaked at $152K in Q4 2021. 27 funds tracked by Wall St. Rank hold BIOC as of Q1 2022.

Bailard reported no remaining Biocept, Inc. position as of Q1 2022 after selling out during the quarter.
Bailard sold 1,403 Biocept, Inc. shares in Q1 2022, an estimated $152K.
Bailard first reported a position in Biocept, Inc. in Q4 2021 and held it in 1 quarter.
Bailard's Biocept, Inc. position peaked at $152K in Q4 2021.
27 funds tracked by Wall St. Rank held Biocept, Inc. as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.